Maxillofacial/ENT surgery
EXPERIENCE THE BENEFIT OF SIMULTANEOUSLY CO-APPLY SUBSTANCES
Maxillofacial/ENT surgery
Infections, haemorrhage and injury to bones and tissue are common challenges that surgeons are faced with during maxillofacial/ENT surgery. Vivostat® solutions have been used with great benefit in a variety of maxillofacial/ENT procedures including:
- Alveoplasty
- Bisphosphonate-related osteonecrosis of the jaws
- Cystic fibrosis
- Endoscopy surgery
- ENT oncology surgery
- Facial trauma surgery
- Oral/head neck cancer treatment
- Sinus surgery
Despite remarkable advances in surgical techniques and technology, surgeons are still faced with many challenges within maxillofacial/ENT surgery. Vivostat® meet these challenges, offering solutions for:
- Infection prevention and treatment
- Control of bleeding
- Sealing and filling of dead space
- Accelerating tissue regeneration and wound healing
The Vivostat® Systems provides surgeons with a choice of two remarkable products to address these challenges effectively.
If haemostasis and/or sealing are the primary challenges, Vivostat® Fibrin is an excellent choice. When tissue regeneration and wound healing is priority, Vivostat® PRF is the optimal solution.
For both Vivostat® Fibrin and Vivostat® PRF the Vivostat® Co-Delivery system enables co-application of up to 5.3 ml of a desired substance, e.g. antibiotics, cells, etc. The substance will be embedded in the product ensuring protection of the substance and sustained release/impact of the substance. The great advantage of this is that the affected area is specifically targeted launching a possible higher local dose of the substance, but at the same time possibly a lower systemic dose.
main advantages using vivostat®
- Prevention and control of infections
- Haemostasis of bleedings
- Sealing and filling of dead space (supporting bone grafts)
- Accelerating tissue regeneration and wound healing
UNIQUE APPLICATION DEVICES - WITH OR WITHOUT CO-DELIVERY
As part of the Vivostat® System you also find a wide range of different application devices for various types of surgery – open surgery, endoscopy, laparoscopy and robotic surgery.
In maxillofacial/ENT surgery most often the Vivostat® Endoscopic catheter is used. As the Vivostat® Endoscopic catheter has a preformed nozzle, the spray tip can easily be manipulated in many directions ensuring control of the application for the surgeon.
For open surgery you may choose from the Vivostat® Spraypen or the Vivostat® Spraypen – Concorde. The concorde spraypen has a pre-bent tip allowing surgeons to reach difficult areas like the backside of a kidney. Both spraypens are designed to deliver the sealant/matrix to the surgical site in a precise and targeted manner, without experiencing the blockage that is common in conventional sealant systems – in fact, the application devices in the Vivostat® System all allows for the surgeon to deliver the solution intermittently.
Vivostat® Co-Delivery
The revolutionary system makes it possible to co-apply e.g. stem cells or antibiotics with the Vivostat® product.
Vivostat® PRF
Using the Vivostat® System, you can prepare autologous platelets with multiple growth factors embedded in a matrix.
Pelaz, A., Junquera, L., Gallego, L., Garcı́a-Consuegra, L., Junquera, S., & Gómez, C. G. (2014), Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws – A pilot study comparing fibrin rich in growth factors and teriparatid, Medicina Oral Patologia Oral y Cirugia Bucal e–e, e320–e326, https://doi.org/10.4317/medoral.19458
Giudice, G., Cutrignelli, D., Leuzzi, S., Robusto, F., Sportelli, P., & Nacchiero, E. (2015), Autologous bone grafting with platelet-rich plasma for alveolar cleft repair in patient with cleft and palate, Annali Italiani di Chirurgia, 87, 5–12, https://pubmed.ncbi.nlm.nih.gov/27026208/
Aaaes, K., Nielsen, K. G., Arndal, E., Von Buchwald, C., Pressler, T., & Hoiby, N. (2021), Autologous fibrin sealant co delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery, Acta OtoLaryngologica, 141(2), 181–186, https://doi.org/10.1080/00016489.2020.1841909
